The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Open accessAbstract
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer.Methods We did this phase 2, single-arm trial at 27 sites (academic, hospital, and private cancer centres) in France, Germany, Italy, and USA. Patients who had received two or more previous treatments received intravenous nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects. The primary endpoint was the proportion of patients with a confirmed objective response as assessed by an independent radiology review committee. We included all treated patients in the analyses. This study is registered with ClinicalTrials.gov, number NCT01721759.Findings Between Nov 16, 2012, and July 22, 2013, we enrolled and treated 117 patients. 17 (14·5%, 95% CI 8·7-22·2) of 117 patients had an objective response as assessed by an independent radiology review committee. Median time to response was 3·3 months (IQR 2·2-4·8), and median duration of response was not reached (95% CI 8·31-not applicable); 13 (77%) of 17 of responses were ongoing at the time of analysis. 30 (26%) of 117 patients had stable disease (median duration 6·0 months, 95% CI 4·7-10·9). 20 (17%) of 117 patients reported grade 3-4 treatment-related adverse events, including: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and diarrhoea (three [3%]). There were two treatment-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple comorbidities in the setting of progressive disease.Interpretation Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These data support the assessment of nivolumab in randomised, controlled, phase 3 studies of first-line and second-line treatment.Funding Bristol-Myers Squibb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The expression of PD-L1 was neither prognostic nor predictive of clinical benefit in a retrospective analysis using various cut points in this study.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [97]
Experimental — accuracy not yet measuredIn the citing paper
“Nivolumab (BMS-936558, ONO-4538, or MDX1106, trade name Opdivo; Bristol-Myers Squibb, Princeton, NJ, USA) is a first-in-class fully human immunoglobulin G4 (IgG4) monoclonal antibody (mAb) inhibitor that suppresses PD-1 activity through selectively targeting and blocking the interaction between ligands (PD-L1 and PD-L2) and PD-1 receptor [35].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [35]
In the citing paper
“A phase III trial (CheckMate 017) in patients previously treated for SCC compared 3 mg/kg of nivolumab given every 2 weeks with docetaxel, showing an improvement of 3.2 months [97,98]”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citation
Cited by
Sorted by citations
Items 201–300 of 1,000
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.002 · Cited by 144
French Endocrine Society guidance on endocrine side effects of immunotherapy
Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0320 · Cited by 140
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon
Rolfo, C. D., Caglevic, C., Santarpía, M., Araújo, A., Giovannetti, E., Gallardo, C. D., Pauwels, P., & Mahave, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53156-4_5 · Cited by 145
Endocrinological side-effects of immune checkpoint inhibitors
Torino, F., Corsello, S. M., & Salvatori, R. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000293 · Cited by 138
Fernández-Poma, S. M., Salas‐Benito, D., Lozano, T., Casares, N., Riezu‐Boj, J. I., Mancheño, U., Elizalde, E., Alignani, D., Zubeldia, N., Otano, I., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0236 · Cited by 138
Wang, Y., Kim, T. H., Fouladdel, S., Zhang, Z., Soni, P., Qin, A., Zhao, L., Azizi, E., Lawrence, T. S., Ramnath, N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36096-7 · Cited by 145
Ocular and orbital side-effects of checkpoint inhibitors: a review article
Antoun, J., Titah, C., & Cochereau, I. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000296 · Cited by 139
NK Cell-Based Immunotherapies in Cancer
Shin, M. H., Kim, J., Lim, S. A., Kim, J. H., Kim, S., & Lee, K. (2020) · Immune Network · doi:10.4110/in.2020.20.e14 · Cited by 141
written on behalf of the AME Academic Lung Cancer Cooperation Group, Hu, Y., Zhang, Q., Li, H., Michot, J., Liu, H., Zhan, P., Lv, T., & Song, Y. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.12.10 · Cited by 136
COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link
Bozinovski, S., Vlahos, R., Anthony, D., McQualter, J. L., Anderson, G. P., Irving, L. B., & Steinfort, D. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13198 · Cited by 138
Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?
Kerr, K. M., & Hirsch, F. R. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0522-sa · Cited by 135
Chemotherapy remains an essential element of personalized care for persons with lung cancers
Hellmann, M. D., Li, B., Chaft, J. E., & Kris, M. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw271 · Cited by 136
PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
Xu, X., Hou, B., Fulzele, A., Masubuchi, T., Zhao, Y., Wu, Z., Hu, Y., Jiang, Y., Ma, Y., Wang, H., et al. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.201905085 · Cited by 135
Planchard, D., Yokoi, T., McCleod, M., Fischer, J. R., Kim, Y., Ballas, M. S., Shi, K., & Soria, J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.003 · Cited by 130
Self-citationBerghoff, A. S., Ricken, G., Wilhelm, D., Rajky, O., Widhalm, G., Dieckmann, K. U., Birner, P., Bartsch, R., & Preusser, M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2216-8 · Cited by 131
Dramatic enhancement of the detection limits of bioassays via ultrafast deposition of polydopamine
Li, J., Baird, M. A., Davis, M. A., Tai, W., Zweifel, L. S., Waldorf, K. M. A., Gale, M., Rajagopal, L., Pierce, R. H., & Gao, X. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0082 · Cited by 132
Sideras, K., Biermann, K., Verheij, J., Takkenberg, R. B., Mancham, S., Hansen, B. E., Schutz, H. M., de Man, R. A., Sprengers, D., Buschow, S. I., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1273309 · Cited by 130
Prickett, T. D., Crystal, J. S., Cohen, C. J., Pasetto, A., Parkhurst, M. R., Gartner, J. J., Yao, X., Wang, R., Gros, A., Li, Y. F., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0215 · Cited by 126
Targeted Therapy and Immunotherapy for Lung Cancer
Naylor, E. C., Desani, J., & Chung, P. K. (2016) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2016.02.011 · Cited by 129
Bi, K., Wei, X.-G., Qin, X., & Li, B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00424 · Cited by 127
An update in clinical utilization of photodynamic therapy for lung cancer
Wang, K., Yu, B., & Pathak, J. L. (2020) · Journal of Cancer · doi:10.7150/jca.51537 · Cited by 125
Abdel-Rahman, O. M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.007 · Cited by 124
Yang, C., Lin, M., Chang, Y., Wu, C., & Yang, P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.033 · Cited by 122
Multiparametric profiling of non–small-cell lung cancers reveals distinct immunophenotypes
Lizotte, P. H., Ivanova, E. V., Awad, M. M., Jones, R. E., Keogh, L., Liu, H., Dries, R., Almonte, C. G., Herter-Sprie, G. S., Santos, A. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89014 · Cited by 123
Papavassiliou, A. G., & Musti, A. M. (2020) · Cells · doi:10.3390/cells9112470 · Cited by 124
Queirolo, P., & Spagnolo, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.002 · Cited by 121
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Liu, B., Song, Y., & Liu, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0541-9 · Cited by 122
Tumors evade immune cytotoxicity by altering the surface topology of NK cells
Zheng, X., Hou, Z., Qian, Y., Zhang, Y., Cui, Q., Wang, X., Shen, Y., Liu, Z., Zhou, Y., Fu, B., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01462-9 · Cited by 121
Immune checkpoint inhibitors in advanced non–small cell lung cancer
Assi, H. I., Kamphorst, A. O., Moukalled, N. M., & Ramalingam, S. S. (2017) · Cancer · doi:10.1002/cncr.31105 · Cited by 123
Self-citationRitchie, G. E., Gasper, H. M., Man, J., Lord, S. J., Marschner, I. C., Friedlander, M. L., & Lee, C. K. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5236 · Cited by 121
A concise review on cancer treatment methods and delivery systems
Bidram, E., Esmaeili, Y., Ranji‐Burachaloo, H., Al-Zaubai, N., Zarrabi, A., Stewart, A. G., & Dunstan, D. E. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101350 · Cited by 130
Pierini, S., Gabbasov, R. T., Oliveira-Nunes, M. C., Qureshi, R., Worth, A. M., Huang, S., Nagar, K. K., Griffin, C., Lian, L., Yashiro–Ohtani, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55770-1 · Cited by 123
Recent advances in the clinical development of immune checkpoint blockade therapy
Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 119
Kumar, P., Saini, S., & Prabhakar, B. S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.01.006 · Cited by 117
Shien, K., Papadimitrakopoulou, V. A., & Wistuba, I. I. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.016 · Cited by 119
Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy
Morelli, T., Fujita, K., Redelman‐Sidi, G., & Elkington, P. T. (2021) · Thorax · doi:10.1136/thoraxjnl-2021-217260 · Cited by 116
Ali, O. H., Diem, S., Markert, E., Jochum, W., Kerl, K., French, L. E., Speiser, D. E., Früh, M., & Flatz, L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1231292 · Cited by 117
Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Rosenblatt, J. M., & Avigan, D. (2016) · Blood · doi:10.1182/blood-2016-08-731885 · Cited by 117
Nishino, M., Tirumani, S. H., Ramaiya, N. H., & Hodi, F. S. (2015) · European Journal of Radiology · doi:10.1016/j.ejrad.2015.03.017 · Cited by 115
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 117
Nishino, M., Ramaiya, N. H., Chambers, E. S., Adeni, A. E., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0193-2 · Cited by 117
MHC class II expression in lung cancer
He, Y., Rozeboom, L. M., Rivard, C. J., Ellison, K. E., Dziadziuszko, R., Yu, H., Zhou, C., & Hirsch, F. R. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.030 · Cited by 115
Rosato, R. R., Dávila‐González, D., Choi, D. S., Qian, W. P., Chen, W., Kozielski, A. J., Wong, H. H., Dave, B., & Chang, J. C. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1037-4 · Cited by 115
Huang, D., Chen, X., Zeng, X., Lao, L., Li, J., Xing, Y., Lu, Y., Ouyang, Q., Chen, J., Yang, L., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00939-9 · Cited by 114
Zheng, S.-J., Yang, M., Luo, J., Liu, R., Song, J., Chen, Y., & Du, J. (2023) · ACS Nano · doi:10.1021/acsnano.3c03962 · Cited by 114
Chae, Y. K., Pan, A. P., Davis, A. A., Raparia, K., Mohindra, N. A., Matsangou, M., & Giles, F. J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.011 · Cited by 116
Noll, B., Wang, W., Gong, Y., Zhao, J., Kalhor, N., Prieto, V. G., Staerkel, G., & Roy‐Chowdhuri, S. (2018) · Cancer Cytopathology · doi:10.1002/cncy.21987 · Cited by 116
O’Connor, J. M., Fessele, K. L., Steiner, J., Seidl-Rathkopf, K., Carson, K. R., Nussbaum, N. C., Yin, E. S., Adelson, K. B., Presley, C. J., Chiang, A. C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0798 · Cited by 114
Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications
Vuong, J. T., Stein-Merlob, A. F., Nayeri, A., Sallam, T., Neilan, T. G., & Yang, E. H. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.048 · Cited by 116
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Botticelli, A., Onesti, C. E., Zizzari, I. G., Cerbelli, B., Sciattella, P., Occhipinti, M. A., Roberto, M., Pietro, F. R. D., Bonifacino, A., Ghidini, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22242 · Cited by 113
Patel, M. R., Jacobson, B. A., Ji, Y., Drees, J. J., Tang, S., Xiong, K., Wang, H., Prigge, J. E., Dash, A. S., Kratzke, A. K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5320 · Cited by 114
Nomizo, T., Ozasa, H., Tsuji, T., Funazo, T. Y., Yasuda, Y., Yoshida, H., Yagi, Y., Sakamori, Y., Nagai, H., Hirai, T., et al. (2017) · Scientific Reports · doi:10.1038/srep45124 · Cited by 110
Berger, K., & Pu, J. J. (2017) · Gene · doi:10.1016/j.gene.2017.09.050 · Cited by 113
Combinatorial Cancer Immunotherapies
Hellmann, M. D., Friedman, C. F., & Wolchok, J. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.005 · Cited by 112
Feng, Y., Wang, X., Bajaj, G., Agrawal, S., Bello, A., Lestini, B. J., Finckenstein, F. G., Park, J.-S., & Roy, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2842 · Cited by 109
Self-citationThompson, J. C., Carpenter, E. L., Silva, B. A., Rosenstein, J., Chien, A. L., Quinn, K., Espenschied, C. R., Mak, A. J., Kiedrowski, L. A., Lefterova, M. I., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00321 · Cited by 108
Global mapping of cancers: The Cancer Genome Atlas and beyond
Ganini, C., Amelio, I., Bertolo, R. G., Bove, P., Buonomo, O. C., Candi, E., Cipriani, C., Daniele, N. D., Juhl, H. H., Mauriello, A., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13056 · Cited by 110
Immuno-oncology combinations: raising the tail of the survival curve
Harris, S. J., Harris, S. J., Brown, J. S., Lopez, J. S., Yap, T. A., Brown, J. S., Lopez, J. S., & Yap, T. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0015 · Cited by 110
Peters, S., Reck, M., Smit, E. F., Mok, T. S. K., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz109 · Cited by 108
Hitting the Target: How T Cells Detect and Eliminate Tumors
Zamora, A. E., Crawford, J. C., & Thomas, P. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701413 · Cited by 109
Petrelli, F., Ardito, R., Borgonovo, K., Lonati, V., Cabiddu, M., Ghilardi, M., & Barni, S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.129 · Cited by 107
Advances in Immunotherapy for Glioblastoma Multiforme
Huang, B., Zhang, H., Gu, L., Ye, B., Jian, Z., Stary, C. M., & Xiong, X. (2017) · Journal of Immunology Research · doi:10.1155/2017/3597613 · Cited by 106
Gauvain, C., Vauléon, E., CHOUAID, C., Rhun, É. L., Jabot, L., Scherpereel, A., Vinas, F., Cortot, A. B., & Monnet, I. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.12.008 · Cited by 105
Self-citationWang, P., Ting-jian, W., Yang, Y., Yao, K., Li, Z., Li, Y. M., & Yan, C. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2844-2 · Cited by 105
Kambhampati, S., Bauer, K., Bracci, P. M., Keenan, B. P., Behr, S. C., Gordan, J. D., & Kelley, R. K. (2019) · Cancer · doi:10.1002/cncr.32206 · Cited by 104
The biological functions and clinical applications of exosomes in lung cancer
Chen, R., Xu, X., Qian, Z., Zhang, C., Niu, Y., Wang, Z., Sun, J., Zhang, X., & Yu, Y. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03233-y · Cited by 105
The network of immunosuppressive pathways in glioblastoma
Mangani, D., Weller, M., & Roth, P. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.011 · Cited by 110
Myasthenia triggered by immune checkpoint inhibitors: New case and literature review
Gonzalez, N. L., Puwanant, A., Lu, A., Marks, S. M., & Živković, S. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.01.002 · Cited by 103
Predicting tumour mutational burden from histopathological images using multiscale deep learning
Jain, M. S., & Massoud, T. F. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-0190-5 · Cited by 103
Saigí, M., Alburquerque-Béjar, J. J., Leer, A. M., Pereira, C. A., Pros, E., Romero, O. A., Baixeras, N., Esteve‐Codina, A., Nadal, E., Brambilla, E. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0267 · Cited by 104
Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100
Hanna, N. H., Johnson, D. H., Temin, S., & Masters, G. A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.026716 · Cited by 105
Bailey, S. R., Nelson, M. H., Majchrzak, K., Bowers, J. S., Wyatt, M. M., Smith, A. S., Neal, L. R., Shirai, K., Carpenito, C., June, C. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01867-9 · Cited by 100
Farren, M. R., Mace, T. A., Geyer, S. M., Mikhail, S., Wu, C. S.-Y., Ciombor, K. K., Tahiri, S., Ahn, D. H., Noonan, A. M., Villalona-Calero, M. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1732 · Cited by 101
Renal complications of immune checkpoint blockade
Murakami, N., Motwani, S. S., & Riella, L. V. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.004 · Cited by 100
Semper, H., Muehlberg, F. L., Schulz‐Menger, J., Allewelt, M., & Grohé, C. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.025 · Cited by 98
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
Sharma, G. G., Mota, I. A., Mologni, L., Patrucco, E., Gambacorti-Passerini, C. B., & Chiarle, R. (2018) · Cancers · doi:10.3390/cancers10030062 · Cited by 100
Signaling pathways in brain tumors and therapeutic interventions
Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 105
Renal effects of immune checkpoint inhibitors
Izzedine, H., Mateus, C., Boutros, C., Robert, C., Rouvier, P., Amoura, Z., & Mathian, A. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw382 · Cited by 98
Xue, S., Hu, M., Li, P., Ma, J., Xie, L., Teng, F., Zhu, Y., Fan, B., Mu, D., & Yu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17922 · Cited by 98
Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles
Cho, J. H. (2017) · Immune Network · doi:10.4110/in.2017.17.6.378 · Cited by 102
Does patient age influence anti-cancer immunity?
Pawelec, G. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0697-6 · Cited by 97
Fang, Y., Mo, F., Shou, J., Wang, H., Luo, K., Zhang, S., Han, N., Li, H., Ye, S., Zhou, Z. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2881 · Cited by 98
Iijima, Y., Hirotsu, Y., Amemiya, K., Ooka, Y., Mochizuki, H., Oyama, T., Nakagomi, T., Uchida, Y., Kobayashi, Y., Tsutsui, T., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.004 · Cited by 95
Wu, J., Hong, D., Zhang, X., Lu, X., & Miao, J. (2017) · Scientific Reports · doi:10.1038/srep44173 · Cited by 96
Xie, K., Xu, L., Wu, H., Liao, H., Luo, L., Liao, M., Gong, J., Deng, Y., Yuan, K., Wu, H. M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1404214 · Cited by 96
The balancing act: Immunology of leishmaniosis
Toepp, A. J., & Petersen, C. A. (2020) · Research in Veterinary Science · doi:10.1016/j.rvsc.2020.02.004 · Cited by 94
The Role of Immune Checkpoint Inhibitors in Cancer Therapy
Basudan, A. (2022) · Clinics and Practice · doi:10.3390/clinpract13010003 · Cited by 99
Katsuya, Y., Horinouchi, H., Asao, T., Kitahara, S., Goto, Y., Kanda, S., Fujiwara, Y., Nokihara, H., Yamamoto, N., WATANABE, S.-I. I., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.007 · Cited by 95
Regan, D. P., Chow, L., Das, S., Haines, L., Palmer, E., Kurihara, J. N., Coy, J. W., Mathias, A., Thamm, D. H., Gustafson, D. L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2105 · Cited by 92
Fujisawa, Y., Yoshino, K., Fujimura, T., Nakamura, Y., Okiyama, N., Ishitsuka, Y., Watanabe, R., & Fujimoto, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00046 · Cited by 92
Fang, H., Guo, Z., Chen, J., Lin, L., Hu, Y., Li, Y., Tian, H., & Chen, X. (2021) · Nature Communications · doi:10.1038/s41467-021-27078-x · Cited by 92
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
Yamamoto, N., Nokihara, H., Yamada, Y., Shibata, T., Tamura, Y., Seki, Y., Honda, K., Tanabe, Y., Wakui, H., & Tamura, T. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0411-2 · Cited by 91
Wang, X., Feng, Y.-Y., Bajaj, G., Gupta, M., Agrawal, S., Yang, A., Park, J.-S., Lestini, B. J., & Roy, A. K. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12133 · Cited by 91
Self-citationPotential biomarker for checkpoint blockade immunotherapy and treatment strategy
Dong, Z., Wu, S.-P., Liao, R.-Q., Huang, S., & Wu, Y.-L. L. C. (2016) · Tumor Biology · doi:10.1007/s13277-016-4812-9 · Cited by 90
Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients
Cao, J., Hu, J., Liu, S., Meric‐Bernstam, F., Abdel‐Wahab, R., Xu, J., Li, Q., Yan, M.-L., Feng, Y., Lin, J., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.18.00414 · Cited by 91
Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody
Zhang, L., Geng, Z., Hao, B., & Geng, Q. (2022) · Cancer Control · doi:10.1177/10732748221111296 · Cited by 92
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1
Jin, Z., & Yoon, H. H. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.08.06 · Cited by 90
Nishino, M., Dahlberg, S. E., Adeni, A. E., Lydon, C., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1434 · Cited by 89
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
Zhang, J., Medeiros, L. J., & Young, K. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00351 · Cited by 91
Metadata
- Authors
- Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Souquet, P.-J., Baldini, E., Cappuzzo, F., Chouaid, C., Dowlati, A., Sanborn, R., Lopez-Chavez, A., Grohe, C., Huber, R. M., Harbison, C. T., Baudelet, C., Lestini, B. J., & Ramalingam, S. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Institut Gustave Roussy (FR)
- University of North Carolina at Chapel Hill (US)
- Roswell Park Comprehensive Cancer Center (US)
- Moffitt Cancer Center (US)
- Vanderbilt University (US)
- Azienda Ospedaliera S.Maria (IT)
- Hôpital Civil, Strasbourg (FR)
- The Ohio State University Wexner Medical Center (US)
- UC Davis Comprehensive Cancer Center (US)
- Mount Sinai Beth Israel (US)
- Lehigh Valley Hospital (US)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- University Hospital Cologne (DE)
- Hospices Civils de Lyon (FR)
- Ospedale di Livorno (IT)
- University Hospitals of Cleveland (US)
- Providence Portland Medical Center (US)
- German Center for Lung Research (DE)
- Princeton University (US)
- Emory University (US)
- Corresponding author
- Rizvi, Naiyer A
- ORCID
- Rizvi, Naiyer A
- Mazières, Julien
- Planchard, David
- Stinchcombe, Thomas E
- Dy, Grace K
- Antonia, Scott J
- Horn, Leora
- Mennecier, Bertrand
- Otterson, Gregory A
- Campos, Luis T
- Gandara, David R
- Levy, Benjamin P
- Nair, Suresh G
- Zalcman, Gérard
- Wolf, Jürgen
- Cappuzzo, Federico
- Chouaid, Christos
- Dowlati, Afshin
- Sanborn, Rachel
- Huber, Rudolf M
- Ramalingam, Suresh S
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 16
- Issue
- 3
- Pages
- 257-265
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC5726228
- OpenAlex
- W2106511606
- Cited by
- 1,415
- References
- 36
- Citations by year
- 2026: 23 · 2025: 35 · 2024: 62 · 2023: 84 · 2022: 81 · 2021: 114 · 2020: 128 · 2019: 135 · 2018: 179 · 2017: 228 · 2016: 229 · 2015: 111
- FWCI
- 108.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- PD-1 inhibitors, lung squamous cell carcinoma, refractory lung cancer, objective response rate, treatment safety, pneumonitis, immune-related adverse events, immune checkpoint blockade, non-relapse mortality, ischemic stroke, pneumonia, fatigue, diarrhea, previously treated patients, duration of response, stable disease, time to response
- MeSH terms
- Nivolumab, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Administration Schedule, Europe, Female, Humans, Infusions, Intravenous, Lung Neoplasms, Male, Middle Aged, Risk Factors, Time Factors, United States, Signal Transduction, Comorbidity, Treatment Outcome, Disease Progression, Disease-Free Survival, Kaplan-Meier Estimate, Molecular Targeted Therapy, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
